Seroatlas · Human Serome Atlas

AKR1C8

Aldo-keto reductase family 1 member C8

Also known as: AKCL1_HUMAN, AKR1C8P, AKR1CL1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q5T2L2
Gene: AKR1C8
Ensembl: ENSG00000264006
Chromosome: 10
Canonical length: 326 aa
Protein class: Predicted intracellular proteins

OverviewNCBI Gene

Predicted to enable aldo-keto reductase (NADPH) activity and estradiol 17-beta-dehydrogenase [NAD(P)+] activity. Predicted to be involved in prostaglandin biosynthetic process. Predicted to be located in cytoplasm. [provided by Alliance of Genome Resources, Apr 2025]

Canonical amino-acid sequenceUniProt

326 residues, UniProt reviewed canonical sequence.

>Q5T2L2|AKR1C8
     1  MMTDLKQSHS VRLNDGPFMP VLGFGTYAPD HTPKSQAAEA TKVAIDVGFR HIDSAYLYQN
    61  EEEVGQAIWE KIADGTVKRE EIFYTIKLWA TFFRAELVHP ALERSLKKLG PDYVDLFIIH
   121  VPFAMKPGKE LLPKDASGEI ILETVELCDT WEALEKCKEA GLTRSIGVSN FNHKLLELIL
   181  NKPGLKYKPT CNQVECHPYL NQSKLLEFCK SKDIVLVAYS ALGSQRDPQW VDPDCPHLLE
   241  EPILKSIAKK HSGSPGQVAL RYQLQRGVVV LAKSFSQERI KENFQIFDFE LTPEDMKAID
   301  GLNRNLRYDK LQFAANHPYF PFSEEY

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against AKR1C8 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.23
Highest tissue expression: 6.7 nTPM

Expression across tissuesHPA

Tissue

liver: 6.7 nTPM
epididymis: 2.8 nTPM
choroid plexus: 0.4 nTPM
pancreas: 0.3 nTPM
testis: 0.2 nTPM
adipose tissue: 0.1 nTPM

Single-cell type

choroid plexus epithelial cells: 55 nCPM
hepatocytes: 54 nCPM
adipocytes: 37 nCPM
sertoli cells: 31 nCPM
myosatellite cells: 5.4 nCPM
oocytes: 4.6 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

choroid plexus: 6.4 nTPM
hippocampal formation: 0.9 nTPM
amygdala: 0.2 nTPM
cerebral cortex: 0.2 nTPM
midbrain: 0.2 nTPM
white matter: 0.2 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.83
gnomAD pLI: 0

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

oxidoreductase activity

Cellular components

cytoplasm

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads AKR1C8 as an antibody target. Whether an autoantibody or antibody against AKR1C8 could matter depends on whether native AKR1C8 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

AKR1C8 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label AKR1C8 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...